STOCK TITAN

Wave Life Scienc Stock Price, News & Analysis

WVE Nasdaq

Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology leader advancing RNA medicines through its proprietary PRISM platform. This page provides investors and researchers with timely updates on the company's stereopure oligonucleotide therapies targeting genetic disorders.

Access the latest press releases covering clinical trial progress, regulatory milestones, and scientific advancements. Our curated collection includes updates across WVE's pipeline, including programs for Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and neurological conditions.

Key news categories include:
• Clinical development updates
• Strategic research collaborations
• Regulatory pathway announcements
• Scientific publication highlights

Bookmark this page for direct access to primary source materials about WVE's innovative approach to RNA editing and antisense technologies. Monitor critical developments in precision genetic medicine through verified company communications.

Rhea-AI Summary

Wave Life Sciences Ltd. (WVE) reported its third quarter 2020 financial results, highlighting a cash balance of $216.4 million. The company is advancing several clinical trials, including WVE-003 for Huntington's disease and WVE-004 for ALS, with clinical trial applications expected in early 2021. Wave announced its first ADAR editing program targeting alpha-1 antitrypsin deficiency. R&D expenses decreased to $28.3 million from $44.6 million in Q3 2019, while the net loss narrowed to $33.1 million. The company anticipates funding through mid-2023 after a $93.7 million capital raise.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
-
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call on November 9, 2020, at 8:30 a.m. ET to discuss its third quarter 2020 financial results and provide a business update. Investors can access the webcast via the Investor Relations section of the company’s website. Wave focuses on developing genetic medicines for severe diseases using its proprietary PRISM platform, which enables the design and production of stereopure oligonucleotides.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
conferences earnings
-
Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno will present at the Chardan Virtual 4th Annual Genetic Medicines Conference on October 6, 2020, at 4:45 p.m. ET. A live webcast of the presentation will be available on the company's Investor Relations page, with a replay accessible for 90 days post-event. Wave is dedicated to developing transformative genetic medicines using its proprietary PRISM platform to target genetically defined diseases, aiming to improve patients' futures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE), a clinical-stage genetic medicines company, will have its CEO, Paul Bolno, present at the Chardan Virtual 4th Annual Genetic Medicines Conference on October 6, 2020, at 4:45 p.m. ET. The presentation will focus on the company’s commitment to developing life-changing treatments for genetic diseases through its proprietary PRISM platform. A live webcast will be available on the Wave Life Sciences Investor Relations page, with a replay accessible for 90 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences
-
Rhea-AI Summary

Wave Life Sciences announced the pricing of its public offering of 8,333,334 ordinary shares at $12.00 per share, aiming for gross proceeds of approximately $100 million. The offering, slated to close on September 25, 2020, includes a 30-day option for underwriters to purchase an additional 1,250,000 shares. Jefferies, SVB Leerink, and Mizuho Securities are leading the offering, which is registered with the SEC. Funds raised are intended to advance Wave’s clinical-stage genetic medicines development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.74%
Tags
-
Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) announced an underwritten public offering of ordinary shares, hoping to raise capital for its clinical-stage genetic medicines initiatives. The company plans to grant underwriters a 30-day option to buy an additional 15% of shares sold. The offering's completion is subject to market conditions, with no assurance of final terms. The offering will be conducted via a previously filed shelf registration statement, and details will be available in a prospectus supplement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.74%
Tags
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) has announced its participation in upcoming conferences to showcase its ADAR-mediated RNA editing technology and neurology programs targeting Huntington’s disease, ALS, and FTD. The company will present its first ADAR editing data involving ex vivo retina samples from non-human primates. Presentations will also cover Wave’s C9orf72 and SNP3 programs, with clinical trial applications expected in Q4 2020. These developments highlight Wave's commitment to advancing genetic medicines for debilitating diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.98%
Tags
none
-
Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) has announced that Paul Bolno, MD, MBA, the President and CEO, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 11:30 a.m. ET. Investors can access a live webcast of the presentation on the company’s Investor Relations page. Wave Life Sciences focuses on developing life-changing genetic medicines for severe diseases using its proprietary PRISM platform, which allows for the precise design and production of stereopure oligonucleotides.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.38%
Tags
conferences
-
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) announced an upcoming Analyst and Investor Research Webcast on August 25, 2020, focusing on advancements in its neurology pipeline, including preclinical data for the C9orf72 program targeting ALS and FTD. Presentations will be made by key executives, highlighting strategy updates and new data on the PRISM platform. The event aims to showcase Wave's commitment to developing life-changing genetic treatments for severe diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
Rhea-AI Summary

Wave Life Sciences (Nasdaq: WVE) has announced it will host a live webcast and conference call on August 10, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and provide a business update. Interested parties can access the call via the Investor Relations section of the Wave Life Sciences website. The company, focused on delivering genetic medicines, continues to develop therapies for genetically defined diseases utilizing its proprietary PRISMTM platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
conferences earnings

FAQ

What is the current stock price of Wave Life Scienc (WVE)?

The current stock price of Wave Life Scienc (WVE) is $6.96 as of June 23, 2025.

What is the market cap of Wave Life Scienc (WVE)?

The market cap of Wave Life Scienc (WVE) is approximately 1.1B.
Wave Life Scienc

Nasdaq:WVE

WVE Rankings

WVE Stock Data

1.06B
128.97M
16.53%
83.51%
5.97%
Biotechnology
Pharmaceutical Preparations
Link
Singapore
SINGAPORE